收藏切换
Analysis of Efficacy, Safety and Prognostic Factors of First-Line Osimertinib in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
收藏切换
Yawen WANG1, 2, Guojin ZHOU1, 3, Weiheng LIU1, 2, Kejing TANG1, Jing XU4, Jie CHEN1, *
Pharmacy Today | 2026, 36(5) : 387 - 393
Less
收藏切换
Pharmacy Today | 2026, 36(5): 387-393
Analysis of Efficacy, Safety and Prognostic Factors of First-Line Osimertinib in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Full
Yawen WANG1, 2, Guojin ZHOU1, 3, Weiheng LIU1, 2, Kejing TANG1, Jing XU4, Jie CHEN1, *
Affiliations
  • 1.Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
  • 2.School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China
  • 3.Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530012, China
  • 4.Department of Pharmacy, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong 510091, China
Published: 2026-05-25 doi: 10.12048/j.issn.1674-229X.2026.05.011
Outline
收藏切换
OBJECTIVE

To investigate the efficacy and safety of first-line osimertinib in the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), and to analyze the influencing factors of progression-free survival (PFS).

METHODS

The clinical data of patients with EGFR-mutated NSCLC who received first-line osimertinib monotherapy only from January 2019 to December 2022 were collected retrospectively. The primary endpoint was PFS. Survival analysis was performed using the Kaplan-Meier method, and univariate and multivariate Cox regression models were used to analyze the influencing factors of PFS. Meanwhile, the occurrence of adverse events (AEs) was described.

RESULTS

A total of 74 patients were included, with a median PFS of 16.3 months (95%CI=13.2-20.3 months). Subgroup analysis showed that the median PFS of patients with stage ⅢA/ⅣA was significantly longer than that of patients with stage ⅣB (25.1 months vs. 15.0 months, P=0.035). The median PFS of patients with prognostic nutritional index (PNI)≥39.4 was significantly longer than that of patients with PNI <39.4 (17.2 months vs. 10.7 months, P=0.030). Multivariate Cox regression analysis showed that disease stage and PNI were independent influencing factors of PFS. Common AEs included rash, oral ulcer, diarrhea, decreased white blood cell count, and paronychia, mostly grades 1-2.

CONCLUSION

First-line osimertinib shows favorable efficacy with manageable safety in patients with EGFR-mutated NSCLC. Baseline disease stage and PNI are independent factors for disease progression in NSCLC patients receiving first-line osimertinib.

osimertinib  /  EGFR mutation  /  non-small cell lung cancer  /  survival analysis  /  retrospective study
王雅文, 周国进, 刘伟珩, 唐可京, 许静, 陈杰. 奥希替尼一线治疗EGFR突变非小细胞肺癌的疗效、安全性及预后因素分析. 今日药学, 2026 , 36 (5) : 387 -393 . DOI: 10.12048/j.issn.1674-229X.2026.05.011
Yawen WANG, Guojin ZHOU, Weiheng LIU, Kejing TANG, Jing XU, Jie CHEN. Analysis of Efficacy, Safety and Prognostic Factors of First-Line Osimertinib in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer[J]. Pharmacy Today, 2026 , 36 (5) : 387 -393 . DOI: 10.12048/j.issn.1674-229X.2026.05.011
Year 2026 volume 36 Issue 5
110
25
Cite this Article
BibTeX
Article Info
doi: 10.12048/j.issn.1674-229X.2026.05.011
  • Receive Date:2026-03-02
  • Online Date:2026-09-23
  • Published:2026-05-25
Article Data
Affiliations
History
  • Received:2026-03-02
Funding
Affiliations
    1.Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
    2.School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China
    3.Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530012, China
    4.Department of Pharmacy, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong 510091, China
References
Share
https://castjournals.cast.org.cn/joweb/jryx/EN/10.12048/j.issn.1674-229X.2026.05.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT